Quantitative evaluation of the antiretroviral efficacy of dolutegravir

Sarah B. Laskey1 and Robert F. Siliciano1,2
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2Howard Hughes Medical Institute, Baltimore, Maryland, USA.

The second-generation HIV-1 integrase strand transfer inhibitor (InSTI) dolutegravir (DTG) has had a major impact on the treatment of HIV-1 infection. Here we describe important but previously undetermined pharmacodynamic parameters for DTG. We show that the dose-response curve slope, which indicates cooperativity and is a major determinant of antiviral activity, is higher for DTG than for first-generation InSTIs. This steepness does not reflect inhibition of multiple steps in the HIV-1 life cycle, as is the case for allosteric integrase inhibitors and HIV-1 protease inhibitors. We also show that degree of independence, a metric of interaction favorability between antiretroviral drugs, is high for DTG and nucleoside reverse transcriptase inhibitors. Finally, we demonstrate poor selective advantage for HIV-1 bearing InSTI resistance mutations. Selective advantage, which incorporates both the magnitude of resistance conferred by a mutation and its fitness cost, explains the high genetic barrier to DTG resistance. Together, these parameters provide an explanation for the remarkable clinical success of DTG.

Introduction

The second-generation HIV-1 integrase strand transfer inhibitor (InSTI) dolutegravir (DTG) has had dramatic clinical impact, demonstrating both efficacy (1–5) and a high barrier to resistance (6–8). Despite the remarkable success of DTG, its pharmacodynamic properties are incompletely understood.

The clinical efficacy of antiretroviral drugs depends on many factors. The most fundamental is intrinsic antiviral activity, which is a function of both the IC50 and the dose-response curve slope in all pharmacodynamic models (9, 10). Although frequently overlooked, slope is an important determinant of efficacy because of its exponential relationship with inhibition (10, 11). High slopes for HIV-1 protease inhibitors (12) and allosteric integrase inhibitors (ALLINIs) (13–17) reflect inhibition at multiple steps in the viral life cycle. The first-generation InSTI raltegravir has not shown activity at HIV-1 life cycle steps other than integration (13–15), but DTG has not been evaluated for such activity.

The efficacy of antiretroviral combinations also depends on the interaction between the component drugs. Two classic models for combined drug effects, Loewe additivity (18) and Bliss independence (19), predict the expected efficacies of drug combinations given the experimentally determined efficacies of individual component drugs. Loewe additivity assumes that drugs act through the same target; Bliss independence describes drugs that inhibit distinct targets. At clinical drug concentrations, the Loewe model predicts lower combined efficacy than the Bliss model. In practice, antiretroviral drugs do not interact exclusively according to either model. Degree of independence (DI), a scale defined by the Loewe and Bliss models, describes these interactions quantitatively and allows the calculation of instantaneous inhibitory potential (IIP), a metric of combined drug efficacy. IIP correlates with the clinical success of antiretroviral regimens (11), and IIP values for DTG-containing regimens have not been reported.

The genetic barrier to resistance also impacts the clinical success of antiretroviral drugs. Various point mutations confer resistance to first-generation InSTIs, but they confer minimal resistance to DTG (20, 21). HIV-1 replication in the presence of DTG selects for the R263K substitution in vitro (22), but the clinical impact of this mutation is low due to its fitness cost (23). To quantify the genetic barrier to DTG resistance, we evaluated the selective advantage of InSTI resistance mutations (RMs). Selective advantage, which reflects both the degree and the fitness cost of resistance, indicates the likelihood that drug resistance will emerge in vivo.

Using an in vitro infectivity assay and quantitative analysis, we evaluated critical DTG pharmacodynamic parameters. The results of our analyses of slope, DI, IIP, and selective advantage provide a quantitative explanation for the success of DTG-containing regimens.
Results

**DTG dose-response curve.** We measured the DTG dose-response relationship using a single-round infectivity assay (see Methods), which allows for more accurate determination of pharmacodynamic parameters than do multiple-round assays (24). When plotted on a semi-log axis (Figure 1A, top), the DTG dose-response curve is sigmoidal. However, the same dose-response relationship is represented more informatively on a median-effect plot (Figure 1A, bottom), which presents efficacy on a logarithmic scale (10). The slope parameter is easily determined from the median-effect plot. The DTG dose-response curve has a slope of $1.3 \pm 0.1$, significantly higher ($P = 0.0003$) than the slope of 1 that is characteristic of raltegravir, a first-generation INSTI (10, 11). IIP, which equals the number of logs by which a single round of infection is reduced in the presence of drug(s), is given by the formula: $IIP = \log \left[1 + \left(\frac{D}{IC_{50}}\right)^m\right]$, where $D$ is the drug concentration, and $m$ is the slope (10). For DTG at maximal clinical concentration ($C_{\text{max}}$), $IIP = 2.88$. The inhibition produced by DTG at $C_{\text{max}}$ is almost 5-fold higher than that of a hypothetical drug with the same $IC_{50}$ and the slope $m = 1$, characteristic of first-generation INSTIs (Figure 1A, gray curves).

**DTG does not act late in the HIV-1 life cycle.** To determine whether the efficacy of DTG partially reflects activity during late steps of the HIV-1 life cycle (virus assembly, release, and maturation), as is the case for ALLINIs, we designed a modified infectivity assay (Figure 1B, Methods). Maximally activated CD4+ T lymphoblasts were infected with 1 of 2 different inocula containing the same concentrations of drug and virus. The only difference between the inocula was whether viral production occurred in the presence (inoculum A) or absence (inoculum B) of integrase inhibitors. We used raltegravir as a negative control for late life cycle activity and the ALLINI BI-D, which inhibits virion maturation (16, 25), as a positive control.
The difference between virus produced in the presence versus the absence of BI-D is dramatic, with a greater than 2.5-log difference in efficacy at the highest concentration tested (Figure 1C). Inhibition of infection was readily detected when BI-D was present during virion maturation (inoculum A), but not when virus was combined with BI-D after viral production (inoculum B). This is consistent with reports that the IC50 of BI-D as a maturation inhibitor is 13-fold lower than as an integrase inhibitor (16). In sharp contrast with the results obtained with BI-D, there was no difference in infectivity between virus produced in the presence or the absence of raltegravir, with less than 0.2-log difference between inocula A and B at all concentrations tested (Figure 1C, center). These contrasting results for raltegravir and BI-D demonstrate that this assay measures drug effects on late life cycle steps separately from effects on integration.

Using this system, we found no difference in infectivity between virus produced in the presence or the absence of DTG (Figure 1C). Antiretroviral drugs that act at multiple steps of the HIV-1 life cycle have nonlinear dose-response curves with steep slopes (12), which yield high efficacy at clinical concentrations (10–12). Both inocula A and B have DTG dose-response curves with slopes of 1.3 ± 0.1. Although this value is higher than the slope of 1 previously reported for first-generation InSTIs (10, 11), these experiments show that the difference does not reflect activity late in the viral life cycle.

Figure 2. Efficacy of dolutegravir (DTG) alone and in combination with nucleoside analog reverse transcriptase inhibitors. (A) Median-effect curves for individual drugs and drug combinations. Solid lines show experimentally determined dose-response relationships, with color distinguishing the drug(s) used. The gray combination line shows the experimentally measured efficacy of the combination specified in the label above each chart. Dashed lines show the Loewe additivity (red) and Bliss independence (blue) model predictions for combined efficacy given the experimentally determined efficacies of individual drugs. Drug concentrations [D] were chosen so that all drugs would have similar efficacy at [D0]: [D0,DTG] = 52.7 nM; [D0,ABC] = 558 nM; [D0,3TC] = 434 nM; [D0,TDF] = 354 nM; [D0,FTC] = 110 nM. Error bars show the standard deviation of 6 blood donors. Inset pie charts show degree of independence calculated for drug combinations, according to the color scale in the legend. Each pie slice shows the results from a different blood donor. (B) Average instantaneous inhibitory potential (IIP) over a 24-hour dosing period for individual drugs and their combinations. A dashed line at IIP = 5 shows the minimum IIP for a fully suppressive antiretroviral regimen (10). ABC, abacavir; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine.
DTG interacts favorably with NRTIs. To determine the combinatorial pharmacodynamics of DTG, we quantified its activity in combination with nucleoside analog reverse transcriptase inhibitors (NRTIs). Figure 2A shows the dose-response relationships for DTG, abacavir (ABC), lamivudine (3TC), tenofovir disoproxil fumarate (TDF), and emtricitabine (FTC) separately and in combination. The 3-drug combinations shown (ABC/3TC/DTG and TDF/FTC/DTG) are recommended initial regimens (26).

Plotted alongside the empirical dose-response curves in Figure 2A are the Loewe (red dashed) and Bliss (blue dashed) model predictions for the combined effects of each combination. DI, a scale defined by the Loewe and Bliss models, describes drug interactions quantitatively; higher DI values indicate more mechanistic independence and higher regimen efficacy (11). Some drug combinations (gray curves) exhibit an intermediate DI with efficacy between the Loewe and Bliss predictions; other combinations exhibit synergy, defined as a higher combined efficacy than that predicted by the Bliss model. No antagonistic interactions (defined as combined efficacy lower than the Loewe model prediction) have been observed between antiretroviral drugs (11). Pie charts in Figure 2A show DI values for DTG/NRTI combinations. Although DI varies by donor, we found that DTG/ABC/3TC interact according to the Bliss model, and DTG/TDF/FTC interact synergistically. Both combinations show higher antiviral activity than that predicted by the Loewe additivity model, which is most commonly used to predict combined drug effects (11).

DTG-based regimens have sufficient efficacy to suppress viremia. IIP quantifies the number of logs by which a drug or drug combination reduces a single round of HIV-1 infection (10). IIP is a function of...
drug concentration(s), dose-response curve slope, and $IC_{50}$. The IIP for a combination also depends on the interactions between drugs, quantified by DI. IIP correlates closely with clinical success for most antiretroviral drug combinations, although it has been shown to underestimate first-generation InSTIs. Regimens with a combined average IIP greater than 5 throughout the dosing interval typically can control HIV-1 infection in vivo (11). Figure 2B shows average IIP for individual drugs and the combinations DTG/ABC/3TC and DTG/TDF/FTC. Both 3-drug combinations have an average IIP between 6 and 8, representing 6–8 logs of inhibition of a single round of infection and consistent with excellent reported clinical suppression of viremia. Interestingly, the 2-drug combination DTG/3TC, which has shown promise clinically (27), also has an average IIP greater than 5.

DTG has a high genetic barrier to resistance. Figure 3A shows DTG dose-response curves for viruses containing 1 or more InSTI RMs. Individual mutations, including R263K, have a modest effect, increasing the $IC_{50}$ less than 3-fold (Figure 3B). In contrast, single RMs can increase the $IC_{50}$ of first-generation InSTIs by more than an order of magnitude (28). Although RMs can dramatically impact the slopes of dose-response curves for some antiretroviral drugs, the dose-response curve slopes of first-generation InSTIs are consistent across wild-type and drug-resistant viruses (28). We show here that DTG recapitulates this phenotype, as the curves in Figure 3A all have similar slopes (Figure 3C).

IIP, which is a function of dose-response curve slope and $IC_{50}$, can be used to quantify the impact of RMs on the efficacy of DTG (Figure 3, D and E). Individual RMs have minimal impact on the IIP of DTG at $C_{max}$, and the change in IIP due to 2 RMs is comparable to the effect of single RMs on first-generation InSTIs (26).

The ability of drug-resistant HIV-1 to replicate in the presence of drug depends on the magnitude of resistance and the fitness cost of the RM. Figure 3F shows the impact of InSTI RMs on viral fitness, defined as the ratio of in vitro infection levels for wild-type and mutated viruses. Figure 3G shows the selective advantage of each virus, which reflects both the magnitude and the fitness cost of resistance. Importantly, at $C_{max}$, single mutations produce no selective advantage over wild-type. This result is consistent with the rarity of clinical DTG resistance (29). The variant with the greatest selective advantage over wild-type at $C_{max}$ is G140S/Q148R. Together, these 2 RMs cause a 10-fold increase in $IC_{50}$ with only a moderate fitness cost. The G140S mutation, which confers no resistance on its own, is a compensatory mutation for other InSTI RMs (30). Clinical failure of DTG, which is not observed in adherent patients with no prior exposure to integrase inhibitors, does correlate with prior failure of first-generation InSTIs (6).

**Discussion**

The overwhelming clinical success and increasing popularity of DTG suggest the importance of applying a quantitative framework describing antiretroviral therapy (10, 11, 26, 31) to this second-generation InSTI. DTG shares many pharmacodynamic features with first-generation InSTIs, including efficacy restricted to the early HIV-1 life cycle, favorable interactions with NRTIs, and a linear median-effect dose-response curve with a slope that remains consistent despite RMs. However, DTG has a higher dose-response curve slope than first-generation InSTIs, which leads to higher predicted clinical efficacy. The IIP of DTG at its maximal clinical concentration is 2.98, more than 60% higher than that of raltegravir (1.86). Additionally, DTG has a remarkably high barrier to resistance; none of the single RMs we tested conferred substantial selective advantage over wild-type. Importantly, our model predicts sufficient efficacy at clinical concentrations for both ABC/3TC/DTG and TDF/FTC/DTG to completely suppress viremia, consistent with the success of these 2 regimens.

**Methods**

**Single-round phenotypic infectivity assay.** The phenotypic assay used to quantify DTG efficacy alone and in combination against wild-type and mutant HIV-1 has been previously described (10, 11, 28, 32). Briefly, maximally activated primary CD4+ T lymphoblasts from healthy blood donors were treated with varying concentrations of drug(s) and incubated overnight. The cells were then spinoculated with the single-round fluorescent reporter virus NL4-3 ΔEnv-EGFP and incubated for 3 days, after which the proportion of infected cells was quantified by flow cytometry.

**Replication cycle assay.** 293T cells were transfected using Lipofectamine 2000 (Life Technologies) with a plasmid carrying the proviral clone NL4-3 with EGFP in place of the env gene and a separate plasmid carrying the IIIIB env gene to produce single-round fluorescent reporter virus. A second flask of 293T cells
was mock transfected. Six to 7 hours after transfection, the cells were trypsinized and transferred to 96-well plates in media comprised of 45% RPMI, 5% FBS, 50% human serum (Gemini), and 12 mM HEPES. Integrase inhibitors were added to half of the wells to produce the following conditions: (a) transfected 293T cells incubated with drug, (b) transfected 293T cells incubated without drug, (c) mock-transfected 293T cells incubated with drug, and (d) mock-transfected 293T cells incubated without drug (Figure 1B).

After a 48-hour incubation, supernatant was recovered, centrifuged briefly to remove cellular debris, and transferred to a fresh plate. The conditions described above produced supernatant containing the following: (a) virus matured in the presence of drug, (b) virus matured in the absence of drug, (c) drug without virus, and (d) neither virus nor drug. Supernatants 1 and 4 were combined at equal volumes to yield inoculum A, virus produced in the presence of drug. Supernatants 2 and 3 were combined at equal volumes to yield inoculum B, virus and drug that had been incubated separately. Both combinations were used to infect phytohemagglutinin-activated primary CD4+ T lymphoblasts by spinoculation at 1,200 g and 37°C for 2 hours. Infection was measured after 72 hours by EGFP fluorescence on a FACS Calibur (BD).

Materials. The BI-D used in this study was synthesized by James Fuchs (Ohio State University, Columbus, Ohio, USA) and provided by Alan Engelman (Harvard University, Cambridge, Massachusetts, USA).

Statistics. The slopes of raltegravir and DTG were compared with a 2-tailed Mann-Whitney U test. Previously published values were used for the slope, IC50, Cmax, and half-life parameters of ABC, 3TC, TDF, FTC (11), as well as the Cmax and half-life of DTG (33). The IIP for each drug combination according to the Loewe, Bliss, or empirical estimate of combined drug efficacy was calculated for every minute over a 24-hour dosing interval assuming rapid drug penetration. Average IIP over the dosing interval was reported as the average of these values. The average IIP calculation was performed using a python script, which is available as Supplemental material; supplemental material available online with this article; doi:10.1172/jci.insight.90033DS1.

Study approval. This study was approved by the Johns Hopkins Institutional Review Board. All study participants provided informed, written consent.

Author contributions
SBL designed and conducted the experiments and analysis. SBL and RFS wrote the manuscript.

Acknowledgments
This work was supported by the National Institutes of Health (R01 grant AI081600), the Howard Hughes Medical Institute, the Martin Delaney CARE and DARE Collaboratories (NIH grants AI096113, 1U19AI096109), an ARCHE Collaborative Research Grant from the Foundation for AIDS Research (amFAR 108165-50-RGRL), the Johns Hopkins Center for AIDS Research (P30AI094189), and the Bill and Melinda Gates Foundation.

Address correspondence to: Robert F Siliciano, 733 North Broadway, MRB Room 879, Baltimore, Maryland 21205, USA. Phone: 410.955.2958; E-mail: rsiliciano@jhu.edu.


